SHS_543053 YUEK CNOV 14132

A multi-center, randomized, open-label, Phase IV study to investigate the management of pasireotide-induced hyperglycemia with incretin based therapy or insulin in adult patients with Cushing's disease or acromegaly

The study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and safely managed in majority of patients, including those with diabetes at start of pasireotide treatment.

Inclusion Criteria:

Patients greater than or equal to 18 years old
Confirmed diagnosis of Cushing's disease or acromegaly

Exclusion Criteria:

Patients who require surgical intervention
Patients receiving DPP-4 inhibitors or GLP-1 receptor agonists within 4 weeks prior to study entry
HbA1c > 10% at screening
Known hypersensitivity to somatostatin analogues

Other protocol-defined inclusion/exclusion criteria may apply.
Phase IV
NCT02060383
Neurosciences, All Other
Endocrine
Kevin Yuen, M.D.
Novartis
xLauren Lennox
  • Swedish Medical Center